Abbott Moves into Heart Valves with Evalve Deal

The hottest major interventional cardiology company, Abbott, moves into the hottest interventional clinical space, catheter-based heart valve therapy, with the acquisition of Evalve, providing Abbott with a platform to build a structural heart disease device business.

Go to any of the major interventional cardiology clinical conferences these days like TCT or EuroPCR and the hottest therapeutic area is clearly structural heart disease, particularly catheter-based heart valve therapy. Similarly, the hottest major interventional cardiology company is clearly Abbott Vascular, a division of Abbott Laboratories Inc., by virtue of the success of its Xience V drug-eluting stent. Dealmaking logic would dictate that Abbott, which currently does not have a play in structural heart, should do an acquisition to get into the catheter-based heart valve market. Sometimes logic actually prevails in M&A and this is one of those cases, with Abbott acquiring Evalve Inc., the leader in the catheter-based mitral valve space. [See Deal] (See "Evalve: Leading the Valve Revolution," IN VIVO, September 2006 Also see "Evalve: Leading the Valve Revolution" - In Vivo, 1 September, 2006..)

Chip Hance, president of Abbott Vascular, notes that the company has been looking at opportunities to enter the structural heart...

More from Business Strategy

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.